RU2009101785A - Опосредуемое рнк-интерференцией ингибирование киназы aurora в и его сочетания для противоопухолевой терапии - Google Patents

Опосредуемое рнк-интерференцией ингибирование киназы aurora в и его сочетания для противоопухолевой терапии Download PDF

Info

Publication number
RU2009101785A
RU2009101785A RU2009101785/15A RU2009101785A RU2009101785A RU 2009101785 A RU2009101785 A RU 2009101785A RU 2009101785/15 A RU2009101785/15 A RU 2009101785/15A RU 2009101785 A RU2009101785 A RU 2009101785A RU 2009101785 A RU2009101785 A RU 2009101785A
Authority
RU
Russia
Prior art keywords
seq
nucleic acid
acid molecule
short nucleic
sirna
Prior art date
Application number
RU2009101785/15A
Other languages
English (en)
Russian (ru)
Inventor
КРИШНА Аддепалли МУРАЛИ (IN)
КРИШНА Аддепалли МУРАЛИ
ЧАНДРА Видьядхар Редди Гопаварам ЭСВАР (IN)
ЧАНДРА Видьядхар Редди Гопаварам ЭСВАР
Original Assignee
Релайанс Лайф Сайенсиз Пвт Лтд (In)
Релайанс Лайф Сайенсиз Пвт Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Релайанс Лайф Сайенсиз Пвт Лтд (In), Релайанс Лайф Сайенсиз Пвт Лтд filed Critical Релайанс Лайф Сайенсиз Пвт Лтд (In)
Publication of RU2009101785A publication Critical patent/RU2009101785A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2009101785/15A 2006-06-21 2007-06-21 Опосредуемое рнк-интерференцией ингибирование киназы aurora в и его сочетания для противоопухолевой терапии RU2009101785A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN974/MUM/2006 2006-06-21
IN974MU2006 2006-06-21

Publications (1)

Publication Number Publication Date
RU2009101785A true RU2009101785A (ru) 2010-07-27

Family

ID=39051006

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009101785/15A RU2009101785A (ru) 2006-06-21 2007-06-21 Опосредуемое рнк-интерференцией ингибирование киназы aurora в и его сочетания для противоопухолевой терапии

Country Status (8)

Country Link
US (2) US7615627B2 (enExample)
EP (1) EP2037940B1 (enExample)
JP (1) JP2009541304A (enExample)
AU (1) AU2007298506B2 (enExample)
BR (1) BRPI0712004A2 (enExample)
IL (1) IL195943A0 (enExample)
RU (1) RU2009101785A (enExample)
WO (1) WO2008035365A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
WO2012034942A1 (en) 2010-09-13 2012-03-22 Santaris Pharma A/S Compounds for the modulation of aurora kinase b expression
US9226936B2 (en) 2011-10-28 2016-01-05 The Wistar of Anatomy and Biology Methods and compositions for enhancing the therapeutic effect of anti-tumor T cells
WO2014204024A1 (ko) * 2013-06-18 2014-12-24 한국원자력의학원 Hs2st1 유전자 또는 상기 유전자가 암호화하는 단백질에 대한 억제제를 포함하는 세포 노화 유도용 조성물 및 이를 이용한 세포 노화 유도 방법
KR101734308B1 (ko) 2015-01-21 2017-05-12 한국과학기술연구원 siRNA 표적-특이적 전달을 위한 RNA/DNA 나노입자 및 이를 포함하는 전달체
CN117757789A (zh) * 2022-09-26 2024-03-26 领星生物科技（上海）有限公司 用于抑制肿瘤生长的siRNA及其应用
CN116173059B (zh) * 2022-12-16 2024-11-05 福州载基生物科技有限公司 人aurkb基因在制备抗肿瘤药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
WO2002090514A2 (en) 2001-05-07 2002-11-14 Hybridon, Inc. Epidermal growth factor receptorantisense oligonucleotides
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
JP2005278472A (ja) 2004-03-29 2005-10-13 Pharma Design Inc オーロラｂ結合因子ｉｎｃｅｎｐ
US7375212B2 (en) 2004-05-24 2008-05-20 Isis Pharmaceuticals, Inc. Modulation of Aurora B expression

Also Published As

Publication number Publication date
US20100285107A1 (en) 2010-11-11
IL195943A0 (en) 2009-09-01
US8026225B2 (en) 2011-09-27
WO2008035365A8 (en) 2009-07-23
BRPI0712004A2 (pt) 2013-09-17
JP2009541304A (ja) 2009-11-26
WO2008035365A3 (en) 2008-07-31
AU2007298506B2 (en) 2012-04-05
WO2008035365A2 (en) 2008-03-27
US20080038189A1 (en) 2008-02-14
EP2037940B1 (en) 2013-02-13
EP2037940A2 (en) 2009-03-25
US7615627B2 (en) 2009-11-10
AU2007298506A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
Mitomo et al. Downregulation of miR‐138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines
Oh et al. Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras
Jiang et al. Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression
Thammaiah et al. Role of let-7 family microRNA in breast cancer
JP6865169B2 (ja) Ｐ２１遺伝子調節のためのｒｎａ干渉剤
Szczyrba et al. Identification of ZNF217, hnRNP‐K, VEGF‐A and IPO7 as targets for microRNAs that are downregulated in prostate carcinoma
Chen et al. P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2
Liu et al. MiR‐3613‐3p from carcinoma‐associated fibroblasts exosomes promoted breast cancer cell proliferation and metastasis by regulating SOCS2 expression
Liu et al. Overexpressed miR-494 down-regulates PTEN gene expression in cells transformed by anti-benzo (a) pyrene-trans-7, 8-dihydrodiol-9, 10-epoxide
Novakova et al. MicroRNA involvement in glioblastoma pathogenesis
RU2009101785A (ru) Опосредуемое рнк-интерференцией ингибирование киназы aurora в и его сочетания для противоопухолевой терапии
US9683237B2 (en) Multiple targeted RNAI for the treatment of cancers
Guo et al. RNA m6A methylation regulators in ovarian cancer
JP5976643B2 (ja) 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物
Khafaei et al. miR‐9: From function to therapeutic potential in cancer
JP2018507866A (ja) マイクロｒｎａを有効成分として含む癌治療用医薬組成物
Belter et al. Inhibition of miR-21 in glioma cells using catalytic nucleic acids
EP2912181B1 (en) Aptamers, multimeric aptamers and uses thereof
JP2022031642A (ja) アンチセンスオリゴヌクレオチド
Huang et al. RETRACTED ARTICLE: The microRNA-1246 promotes metastasis in non-small cell lung cancer by targeting cytoplasmic polyadenylation element-binding protein 4
JP6895175B2 (ja) エクソソーム分泌阻害剤
CN106661576A (zh) 用于癌症治疗的多靶向RNAi
Chen et al. Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559
CN103314109A (zh) 用于抑制Hif1α表达的siRNA和含有其的抗癌组合物
Wenhao et al. circAP1M2 activates ATG9A‐associated autophagy by inhibiting miR‐1249‐3p to promote cisplatin resistance in oral squamous cell carcinoma

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120723